Risk of cardiac conduction slowing (QRS/PR prolongations) is assessed prior to clinical trials using in vitro and in vivo studies. Understanding the quantitative translation of these studies to the clinical situation enables improved risk assessment in the nonclinical phase.
Introduction
Adverse effects on vital processes involved in heart function are a major cause of drug withdrawal and late-stage attrition (Redfern et al., 2010; Laverty et al., 2011) . Important biomarkers for heart function include the duration of key intervals in the ECG, such as QT, QRS and PR. Identifying the effects on these biomarkers in nonclinical studies is vital for the progression of safe compounds into first clinical trials. Numerous investigations provide insights for predicting risk of prolongation of the heart rate-corrected QT (QTc) interval (Jonker et al., 2005; Gintant, 2011; Chain et al., 2013; Parkinson et al., 2013) . Much less is known of the nonclinical to clinical translation of drug-induced conduction slowing manifested as QRS and PR prolongations, despite their association with an increased risk of cardiovascular (CV) mortality and morbidity, especially in at risk populations (Nada et al., 2013) .
QRS complex duration corresponds to conduction through the ventricular myocardium and is a predictor of sudden cardiac death (Kurl et al., 2012) . In addition, treatment with conduction-slowing drugs (type 1C antiarrhythmics) increased mortality in patients with structural heart disease in the Cardiac Arrhythmia Suppression Trial trials (Epstein et al., 1993) . Drug-induced QRS widening is primarily linked to inhibition of the sodium ion channel Na v 1.5. Recent studies suggest that <10% block of the human Na v 1.5 (hNa v 1.5) may lead to QRS widening in humans (Cordes et al., 2009; Harmer et al., 2011) . Despite limitations, including use-dependency, nonlinear translation to conduction slowing and variability across laboratories and platforms , this suggests that small disturbances in the sodium current are of relevance.
PR interval duration represents time of conduction through the atria and the atrio-ventricular (AV) node, and prolongations are associated with increased risk of atrial fibrillations and death in at risk populations (Cheng et al., 2009) . The primary mechanism for drug-induced PR prolongation is AV block through inhibition of the cardiac L-type calcium (Ca v 1.2) channel (Nada et al., 2013) . In addition to PR prolongation, Ca v 1.2 block can cause bradycardia (slowed heart beat), reduced contractility and sinus arrest. Potential conduction liabilities may be detected by functional human Ca v 1.2 (hCa v 1.2) electrophysiology assays (Cao et al., 2010) or radioligand binding to rat Ca v 1.2 channels (rCa v 1.2) (Morton et al., 2014) . Radioligand binding to the diltiazem site of rCa v 1.2 is the most predictive of contractility in canine myocytes in vitro compared with radioligand binding at the verapamil and nifedipine sites, and conventional and automated functional hCa v 1.2 electrophysiology (Morton et al., 2014) . It is not known why the radioligand binding assay outperforms the functional assay, and as discussed by Morton and colleagues, the converse might be expected to be true. For example, the radioligand assay was performed using rat brain Ca v 1.2, while the functional assay was performed using hCa v 1.2. Also, a functional assay should theoretically detect the effects elicited by binding to any site, while the binding assay is site-specific. PR prolongation may also be caused by Na v 1.5 block causing slowed conduction through the atria (P wave prolongation) and/or the His-Purkinje system (Vaughan Williams, 1992) . Safety margins have to our knowledge not been suggested for hCa v 1.2 inhibition or rCa v 1.2 binding.
During lead identification, different series of molecules are investigated to identify candidate compounds for further optimization. At this stage, in vitro Ca v /Na v studies may be conducted and the results (IC 50 ) obtained used, in the context with other data, to drive chemistry and select compounds to progress into in vivo studies. Later, in vivo investigations of drug-induced CV effects, such as ECG intervals and haemodynamics, are typically conducted in anaesthetized and/or conscious rats, guinea pigs, dogs and non-human primates (Heath et al., 2011; Cros et al., 2012; Erdemli et al., 2012; Marks et al., 2012) , although rats are insensitive to hERG-mediated effects (Mcdermott et al., 2002) . During lead optimization, when a final candidate drug molecule is not yet selected, rodent CV studies may be conducted to evaluate the CV safety risks of a number of often structurally-related molecules, alongside other testing such as efficacy studies. Prior to first time in man (FTIM) studies, ICH S7A/B guidance requires a non-rodent (typically dog or non-human primate) telemetry study to assess CV risk, including QRS/PR changes, as part of the preclinical safety package. Qualitative analyses have confirmed links between hNa v 1.5 inhibition, conduction in isolated rabbit heart tissue and QRS/PR prolongations in dogs and non-human primates (Erdemli et al., 2012) . Also, studies in conscious dog have identified and differentiated QRS effects of two antiarrhythmics (Heath et al., 2011) . In this work, we wish to expand on this knowledge to investigate quantitative in vivo to clinical translations of QRS widening or PR prolongations, applying pharmacokinetic-pharmacodynamic (PKPD) and translational modelling. In this study, two approaches to translation were adopted to quantify the translational relationships between nonclinical effects and clinical QRS and PR prolongations. Firstly, empirical (top-down) in vitro and in vivo to clinical translations were investigated for the antiarrhythmic compounds AZD1305, flecainide, quinidine and verapamil. In the top-down approach, no assumption was made regarding the nature of the translational relationships, and these were visualized by plotting concentrationmatched effects for each compound independently. The translational relationships were used to identify nonclinical effects of each compound corresponding to 10% (~10 ms) QRS widening or 10% (~16 ms) PR prolongation in humans. Thresholds of 10% effect in humans were selected as such effects were deemed clinically relevant and quantifiable in clinical studies, in the absence of generally accepted thresholds for concern (Nada et al., 2013) . Secondly, mechanism-based translation using the operational model (Black and Leff, 1983) was investigated to identify the system parameters linking ion channel effects (measured in vitro) to clinical QRS and PR prolongations induced by AZD1305. In the middle-out approach, the in vitro to clinical translation is quantified by assuming a model for this relationship. While the empirical translations were investigated for all compounds, middle-out modelling was only performed for AZD1305, as high-quality exposure and ECG data were available from a clinical study. In contrast to the first approach, this approach allows direct simulation of clinical effects given the estimated model and any PK curve. Objectives of this study were to (i) compare the translational relationships between in vitro, in vivo and clinical effects on cardiac conduction for four anti-arrhythmic compounds; (ii) identify nonclinical effects corresponding to 10% QRS and PR prolongations in humans; and (iii) quantify the systems parameters describing the relationship between ion channel effects in vitro and clinical QRS and PR prolongations. Results of these analyses will provide a starting point for predicting QRS widening and PR prolongation in humans based on nonclinical observations.
Methods

Compounds
Four anti-arrhythmic compounds were investigated: the proprietary small molecule AZD1305 (Sigfridsson et al., 2012) and the three marketed anti-arrhythmic compounds flecainide, quinidine and verapamil. AZD1305 is a mixed ion channel blocker (hERG, hNa v 1.5 and rCa v 1.2) previously in development for the treatment of atrial fibrillations, which was discontinued due to safety concerns regarding QTc prolongations and TdP risk (Rónaszéki et al., 2011) . Quinidine, flecainide and verapamil are class 1a, 1c and 4 antiarrhythmics respectively.
Nonclinical data
In vivo data were collected from previous studies in routinely conducted AstraZeneca assays in anaesthetized guinea pig (Marks et al., 2012) and the conscious dog (Prior et al., 2009) . All animal care and experimental procedures had local ethics committee approval and conformed to the UK Animals (Scientific Procedures) Act, 1986. Guinea pig and dog studies were conducted as part of routine safety pharmacology validation work, and were not operator/analyst blinded. Animal studies are reported in compliance with the ARRIVE guidelines (Kilkenny et al., 2010; McGrath and Lilley, 2015) .
Guinea pig telemetry data were available for flecainide and verapamil as these compounds were assessed during assay validation, while no data were available for AZD1305 and quinidine. Details of the experimental set-up are described by Marks et al. (2012) . Briefly, exposure and CV biomarkers were investigated in sodium pentobarbitoneanaesthetized guinea pigs using parallel study designs. Four male Dunkin Hartley guinea pigs (weight range 496 to 614 g, age 7-8 weeks; Harlan UK Limited) were randomized to each treatment and vehicle group. Baseline variability was minimized by controlled body temperature and respiratory rate. Animals were housed in groups of two in cages with Aspen chip bedding and sizzle nest (supplied by Datesand Limited, Manchester, UK). Dry pellets (Teklad Global Higher Fibre Guinea-pig Diet 2041; Harlan UK Ltd, Bicester, UK) and water was offered ad libitum and fresh fruits and vegetables daily, and environmental enrichment was provided in the form of chew sticks. Temperature was kept within 16-23°C, and 12/12 h light/dark cycles were maintained. Guinea pigs were prepared under continuous sodium pentobarbitone anaesthesia as previously described (Marks et al., 2012) . Guinea pigs were artificially ventilated following a tracheotomy, and body temperature was controlled using a homeothermic blanket system. Catheters were inserted into the jugular veins for administration of drug and anaesthetic and for blood sampling and into the carotid arteries for monitoring left ventricular and arterial pressure and contractility. Needle electrodes were placed in a lead II configuration for monitoring the ECG. Guinea pigs were allowed to stabilize for 20 min following surgical preparation, monitored continuously during anaesthesia and killed by an overdose of pentobarbitone at the end of the procedure. Lead II ECGs were monitored continuously by needle electrodes during a 20 min stabilization period followed by an i.v. infusion of three 15 min ascending doses and a 30 min washout period. Exposure data were collected and 1 min averages of continuous ECG recordings extracted at 10 time points each. Doses, the achieved exposure and the resulting change in QRS and PR interval durations are summarized in Table 1 .
Details of the experimental set-up for the dog telemetry assays were as described by Prior et al. (2009) and Bergenholm et al. (2016) . Briefly, exposure and CV biomarkers were investigated in conscious male beagle dogs (Dog Breeding Unit, Alderley Park, AstraZeneca; weight 11.2-18.3 kg, age 19-31 months) using crossover study designs. Animals were housed in groups of four or less except during recording days and feeding when they were housed individually. Pen temperature was kept within 20 ± 5°C, and 12/12 h light/dark cycles were maintained. Dry pellet food (350 g SDS-Dog-D3(E) SQC diet) (Special Diet Services Ltd, Essex, UK) was offered in the afternoon and water provided ad libitum, and toys were offered for environmental enrichment. Cardiac effects were monitored using telemetry devices (DSI® PhysioTel) surgically implanted under anaesthesia prior to this study, as previously described (Prior et al., 2009) . The telemetry transmitter was placed in the abdominal muscle and the ECG electrodes sutured in a lead II configuration across the chest. A minimum of 4 week recovery was allowed between surgery and each study. Animal welfare was monitored using CCTV cameras, by examining all animals for abnormal signs prior to the start of dosing and at each blood sampling time point and by recording food consumption. Four dogs were administered, p.o., vehicle, and each treatment dose in single ascending doses was separated by 2-5 days. ECGs were extracted as mean values of five ECG complexes, and data were collected from 1 h pre-dose and at 13 (CV) or 6 (exposure) time points up to 24 h post-dose. Doses, achieved exposure and resulting change in QRS and PR interval durations are summarized in Table 1 .
The relationships between drug concentration and hNa v 1.5 inhibition were simulated using estimates of concentrations at 50% inhibition (IC 50 ) and Hill coefficients (γ) measured by automated IonWorks electrophysiology using hNa v 1.5-transfected Chinese hamster ovary cells (Harmer et al., 2008) . This assay is routinely conducted at AstraZeneca and was consistently evaluated at eight concentrations using physiological pacing rates (3 Hz) for all compounds. Compound interactions with human Ca v 1.2 channels were studied by automated electrophysiology (Morton and Main, 2013; Morton et al., 2014) and with brain Ca v 1.2 channels from male Wistar rats by radioligand binding to the diltiazem, verapamil and nifedipine sites (Morton et al., 2014) (Table 1) . Data from both assays and all binding sites were initially explored, and the estimated concentrations at 50% binding to the diltiazem site (K i ) were chosen to simulate BJP L Bergenholm et al. in vitro Ca v 1.2 effects based on these initial results and the findings by Morton et al. (2014) .
Clinical data
Exposure, QRS and PR intervals following AZD1305 treatment were collected from a randomized, double-blinded and placebo-controlled phase I study in 29 healthy male volunteers. Subjects were assigned to a dose group and thereafter randomized to placebo or treatment. This study was performed in accordance with the ethical principles of the Declaration of Helsinki and is consistent with the International Conference on Harmonisation (ICH)/Good Clinical Practice. Details of this clinical study are described elsewhere (Parkinson et al., 2013) . Healthy volunteers were administered two separate doses of placebo or AZD1305 [six oral doses (10-500 mg) and two i.v. doses (10 and 70 mg)]. Lead II ECGs were monitored continuously and extracted at baseline and at 18 specific time points, and plasma samples were taken pre-dose and at 14 time points within 24 h following dose administration. Literature searches were conducted in Pubmed to identify the clinical effects of flecainide, quinidine and verapamil on QRS and PR. Search criteria and references to the identified studies are described in the Supporting Information S1. Individual exposures together with QRS and PR intervals measured over time or at pre-dose were rarely reported. Therefore, associated pairs of exposure and QRS and PR change from baseline were collected, such as pairs of maximal exposure and effect or exposure and effect sampled at the same time point. Information in text, tables and/or figures was used to extract the data, and percentage change in QRS or PR intervals was converted to change in ms. Additional information collected included number of subjects, dose, route of administration, dosing history and if the subjects were healthy volunteers or patients. Studies of verapamil effects following i.v. administration were excluded to increase consistency with dog data as verapamil more potently induces PR prolongations following i.v. compared with oral administration (Reiter et al., 1982) , primarily due to the different metabolism and potency of its two enantiomers (Echizen et al., 1985a,b) . The data and statistical analysis comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2015) .
Plasma protein binding
Free (unbound) plasma concentrations were calculated using in vitro estimates of plasma protein binding (PPB) for each compound in guinea pig, dog and human plasma by a standard equilibrium dialysis method (Banker et al., 2003) for all compounds except flecainide, where dog PPB was acquired from Heath et al. (2011) . Unbound fractions originated from AZ laboratories, contracting laboratories and literature sources.
Nonclinical to clinical translation
Two approaches were adopted to quantify the translational relationships between nonclinical effects and clinical QRS and PR prolongations ( Figure 1 ).
Translation method 1: top-down (empirical) translation. Empirical translational relationships between in vitro, guinea pig or dog effects and effects in humans were investigated for the antiarrhythmic compounds AZD1305, flecainide, quinidine and verapamil, following the approach visualized in Figure 1A .
Exposure-effect relationships for each compound were characterized in each species using PKPD modelling (all guinea pig and dog data and clinical AZD1305 data) or nonlinear regression (clinical literature data for flecainide, quinidine and verapamil). Monolix 4.3.2 (Lixoft) and MATLAB 2013b (The MathWorks) were used to develop and analyse the models. Detailed methods are described in Bergenholm et al. (2016) (dog PKPD models) and the Supporting Information S1 and S2 (human regression models and guinea pig and human PKPD models respectively). Briefly, a model was developed to describe baseline and drug-induced effects on QRS and PR intervals for each compound in each species. A single-phase cosine function was applied to describe potential circadian variations, and an RR interval correction model was applied to describe potential changes due to heart rate variations, both at baseline and due to drug effects. Direct and delayed (effect compartment) proportional and E max drug effect models were evaluated. Estimated drug effect parameters were extracted from the selected models to simulate the predicted change from baseline. Assuming no uncertainty in the baseline was required as this information was not available for the literature models. Ion channel effects were simulated using the parameters collected in vitro.
The resulting exposure-effect models and the in vitro models were used to simulate QRS or PR prolongations, hNa v 1.5 inhibition or rCa v 1.2 binding at 100 evenly spaced, matched concentrations within the supported concentration ranges. Each translation was investigated at matching total and unbound concentrations by converting the estimated drug effect parameters accordingly, and in ms and percentage change from baseline by scaling the simulated responses. Uncertainty and variability in the estimated drug effects were estimated and visualized by 95% confidence intervals (CIs) for the typical effects and prediction intervals (PIs) for new observations. The CIs provide a range for the estimated average drug effects as predicted by the model and are useful for cross-species translation as they represent the typical behaviour. As CIs represent uncertainty in typical effects, they get tighter as the amount of data increases. PIs provide a range for new observations, take both variability and residuals into account and do not get smaller when the amount of data increases. PIs are therefore wider than CIs, and of importance to predict new data. For the population PKPD models, the CIs and PIs were generated using Monte Carlo methods. CIs were constructed from the covariance matrices of the typical parameters for the PD drug effects and PIs from the estimated typical parameters, between-subject variabilities and residual variabilities; 10 000 randomly sampled parameter sets were simulated and sorted at each concentration, and the 2.5th and 97.5th percentiles were extracted. Non-physiological parameter values (e.g. EC 50 below 0) were removed. CIs and PIs for the regression models based on literature data were produced using the built-in Matlab function predict.
Predicted in vitro, guinea pig and dog effects were plotted against the predicted human effect at matched total and unbound concentrations to visualize the translations for each compound. Nonclinical effects corresponding to a 10% change in humans were extracted.
Translation method 2: middle-out (semi-mechanistic) translation. A middle-out translation method was applied to quantify the in vitro to clinical translation, where a mathematical description for the translational relationship was assumed and quantified. AZD1305 was selected for this analysis as high-quality, highresolution clinical data were available, rather than the literature analyses combining many studies. In vitro and clinical AZD1305 data were combined to estimate the signal transductions from effects at the ion channel level to clinical QRS or PR prolongations using the operational model of agonism (Black and Leff, 1983) as visualized in Figure 1B . The model was applied according to
where c e,u is the predicted unbound drug concentration in the effect compartment, K d the concentration at 50% bound or inhibited receptor, γ the Hill factor of the drug-ion channel interaction, E m the maximal QRS or PR prolongations possible in the system, τ the transducer ratio and n the exponent of the sigmoidal relationship between bound/inhibited ion channel and QRS or PR prolongation. The transducer ratio τ is the ratio of the maximum inhibited/bound ion channels to the inhibited/bound ion channels corresponding to the halfmaximum response. The E m values could not be estimated from the AZD1305 data, as maximum prolongations were not reached, causing practical identifiability issues. For estimation of the remaining parameters to be allowed, the E m values were therefore fixed. A range of E m values (20-100 ms) was investigated by performing parameter estimation and simulating the resulting models. K d and γ were fixed to the in vitro estimates describing the ion channel inhibition or binding. Also, baseline variability was minimized as described in the Supporting Information S2, and an effect compartment was applied to account for the short delay between exposure and QRS and PR effect. The operational model was developed using in vitro and high-quality phase I clinical data for AZD1305. As the operational model has been shown to be structurally identifiable (Janzen et al., 2016) , and assuming that the mechanisms of new compounds are similar, the system-specific parameters of this model (E m , τ and n) may be fixed and effects of compounds predicted by incorporating the in vitro potency (K d and γ) of the new compounds. These predictions were produced for flecainide, quinidine and verapamil by combining their specific in vitro potencies with the estimated systems parameters. These predictions were then compared with the QRS and PR prolongation data collected from the literature study. This can be viewed as a form of validation of the system-specific parameters, as this evaluates the performance of the system model to predict new data on which it was not trained.
Finally, the systems parameters were used to predict QRS and PR prolongations at 0-100% inhibition/binding and generate 95% CIs for this relationship using Monte Carlo methods similar to the PKPD models. Also, percentage inhibition/binding corresponding to 10% QRS or PR prolongations were extracted.
Results
Nonclinical and clinical data
The data acquired are summarized in Table 1 , including effects of the investigated compounds on Na v 1.5 and Ca v 1.2 in vitro and QRS and PR intervals in humans, dogs and guinea pigs. Changes in heart rate and blood pressure were also observed. Both were slightly increased following AZD1305 treatment in dogs and humans and decreased following quinidine, flecainide and verapamil treatment in dogs and verapamil treatment in guinea pigs, while only heart rate was decreased following flecainide treatment in guinea pigs.
Translation to QRS complex widening in humans
Translation method 1: top-down translation to clinical QRS widening. PKPD or regression models were developed to describe drug-induced QRS effects for all compounds, and the parameters describing the drug effects were extracted and simulated to generate the CIs and PIs (Figure 2 and Table 2 ). QRS effects of AZD1305, flecainide and quinidine were described by proportional models in dogs, while the effects of flecainide in guinea pigs were better described by an effect compartment power model. QRS prolongations by AZD1305 and quinidine in humans were captured by proportional models, while a sigmoid model better described the larger prolongations reached following treatment with flecainide. The wide PIs indicate large variability and residuals in the data sets. Details of the PKPD and regression modelling results are described in the Supporting Information S1 and S2 (human regression models and human and guinea pig PKPD models respectively) and in Bergenholm et al. (2016) (dog PKPD models).
Simulated QRS widenings in humans were plotted against in vitro and in vivo effects at matched total or unbound exposures to visualize the translational relationships for each compound. Uncertainty in the mean predictions and variability in the data were visualized by overlaying the CIs and PIs respectively. Nonclinical effects corresponding to 10% QRS widening in humans were extracted. Typical QRS widenings of 10% occurred at unbound concentrations corresponding to 3-7% (CI range 2-9%) hNa v 1.5 inhibition in vitro ( Figure 3A ). This indicates that conduction liabilities may occur well below the IC 50 of a compound, where Hill factors have large impact. Hill factors were 0.75-1.2 for the compounds investigated. Assuming Hill factors of 1 resulted in considerably less consistent translational relationships (2-10% hNa v 1.5 inhibition compared with 3-7% when Hill factors were included). CIs for AZD1305 and quinidine were overlapping, whilst QRS widening by flecainide was larger at equal in vitro changes. For consistent in vitro to human translational relationships between the compounds, it was vital that the unbound fractions were accounted for.
For the in vivo to clinical translations, 10% QRS widening in humans corresponded to 4.6% (CI range: 2.1-9.9) in guinea pig ( Figure 3B ) and 2.3-3.3% (CI range: 0.8-4.5) in dog ( Figure 3C ) at matched total concentrations. The CIs for all three compounds overlapped for the dog to human translation. The guinea pig to human translation was only investigated for flecainide and, therefore, has lower confidence compared to dogs. Guinea pigs were more sensitive for detecting flecainide-induced changes than dogs, while humans were the most sensitive. QRS interval baselines were shorter in guinea pigs and dogs by approximately 75 and 50% respectively. Comparisons of absolute differences, therefore, further increased the translational gap. Similar results were obtained for translating effects of total and unbound drug in vivo as PPB fractions were similar between the species.
Translation method 2: middle-out translation to clinical QRS widening. Identifiability issues led to a high correlation between E m and τ and was solved by fixing E m . All estimates are mean ± SEM. a and b, estimated parameters of the power model; Add. res., estimated additive residuals for the population models; BSV, between-subject variability; E max , estimated maximal effect; k e0 , estimated rate of distribution to the effect compartment; n H , estimated Hill factor; QRS 0 , estimated baseline QRS; slope, proportional unbound drug effect.
Figure 3
Top-down translation to QRS widenings in humans from (A) hNa v 1.5 inhibition in vitro, (B) QRS widenings in guinea pigs and (C) QRS widenings in dogs, by AZD1305 (solid lines), flecainide (dashed lines) and quinidine (dashed-dotted lines). Effects of AZD1305 and quinidine in guinea pigs were not available. The shaded areas represent the 95% CIs (darker areas) and PIs (lighter areas) overlaid for all compounds and species.
Figure 4
Middle-out translation of hNa v 1.5 inhibition to QRS widening in the clinic. (A) Fit to data and typical parameter estimates for the system parameters for the operational model. (B) Model predicted and measured effects of flecainide and quinidine in humans. Predictions were generated using the estimated signal transduction parameters and the in vitro estimated potency in the hNa v 1.5 assay. Clinical data were collected from literature studies and represent effects in healthy volunteers (dark green) and patients (light green). (C) Model predicted translation between hNa v 1.5 inhibition in vitro and QRS widening in humans, highlighting the CI for inhibited ion channel at 10% QRS widening.
Figure 5
PR prolongations in guinea pig (top row), dog (middle row) and humans (bottom row) induced by AZD1305 (left column), flecainide (middle column) and quinidine (right column). Data points represent individual healthy animal/human volunteer change from model-predicted PR baseline against simulated unbound concentration in the plasma (dog) or effect compartment (guinea pig, AZD1305 human) (dots), or associated average unbound exposure-PR pairs with SEMs where available in healthy volunteers (circles) and in patients (squares). The shaded areas represent the 95% CIs (darker area) and PIs (lighter area). Brown colours represent repeated dosing data (human verapamil).
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Goodness-of-fit values were improved when E m was increased from 20 to 40 ms and remained similar up to 100 ms.
Simulations of optimized models with fixed E m values between 40 and 100 ms showed similar predictions up to 20 ms change (Figure in Supporting Information S3). As widenings above 20 ms are unlikely to occur in a safety setting (by a drug not intended to cause QRS widening), and highest observed widenings for all the compounds investigated were 31 ms, an E m value of 40 ms was selected. The selected value for E m influenced the estimated value for τ. The operational model with E m = 40 ms well described AZD1305-induced QRS widenings ( Figure 4A ). Final estimates for τ was high (8.0 ± 0.4), suggesting an efficient signal transduction with some signal amplification, as the exponent n was larger than 1 (1.5 ± 0.1). Baseline and effect compartment parameters were similar to the estimated values in the PKPD models (Supporting Information S2). In order to test whether the systems properties of AZD1305 could be used in the prediction of other compounds, the systems parameters were combined with in vitro potency parameters for flecainide and quinidine and used to predict the QRS widening of these compounds in the measured range of unbound concentrations ( Figure 4B ). QRS widenings induced by quinidine were well predicted, while flecainide effects were slightly under-predicted.
The translational relationship between inhibited hNav1.5 and QRS widening in humans was simulated, and the CIs and PIs were generated ( Figure 4C ). These results indicate that only 6% (CI range: 5-7%) inhibition of hNav1.5 is required to induce 10% QRS widening.
Translation to PR interval prolongation in humans
Translation method 1: top-down translation to clinical PR prolongation. PKPD or regression models were developed to describe drug-induced PR effects for all compounds, and the parameters describing the drug effects were extracted and simulated to generate CIs and PIs ( Figure 5 and Table 3 ). PR effects of AZD1305 and flecainide in dogs were described by proportional models and verapamil by an E max model, and effects of flecainide and verapamil in guinea pigs were described by effect compartment proportional models. PR prolongations by AZD1305 in humans were captured by a proportional model, while sigmoid or E max models better described the larger prolongations reached following treatment with flecainide or verapamil. The wide PIs indicate large variability in the data sets. Details of the PKPD and regression modelling results are described in Supporting Information S1 and S2 (human regression models and Table 3 PD/regression models of AZD1305-, flecainide-and verapamil-induced PR prolongations
AZD1305
Flecainide Verapamil All estimates are mean ± SEM. a and b, estimated parameters of the power model; Add. res., estimated additive residuals for the population models; BSV, between-subject variability; E max , estimated maximal effect; k e0 , estimated rate of distribution to the effect compartment; n H , estimated Hill factor; PR 0 , estimated baseline PR; slope, proportional unbound drug effect.
human and guinea pig PKPD models respectively) and in Bergenholm et al. (2016) (dog PKPD models). Simulated PR prolongations in humans were plotted against in vitro and in vivo effects at matched total or unbound exposures to visualize the translational relationships for each compound. Nonclinical effects corresponding to 10% PR prolongation in humans were extracted. Typical PR prolongations of 10% occurred at unbound concentrations corresponding to 13-21% (CI range 8-24%) rCav1.2 binding at the diltiazem site in vitro ( Figure 6A) . PR prolongations by verapamil were slightly larger than those by AZD1305 and flecainide at equal in vitro effects, although the CIs were largely overlapping. Accounting for the PPB was vital for consistent in vitro to human translational relationships between the compounds.
For the in vivo to clinical translations, 10% PR prolongation in humans corresponded to a 2.3-4.3% change in guinea pigs (CI range: 0.3-7.6) ( Figure 6B ) and 2.4-10% change in dogs (CI range: 1.9-28) ( Figure 6C ) at matched total concentrations. The CIs for flecainide and verapamil overlapped for the guinea pig to human translations and for AZD1305 and verapamil for the dog to human translations, whilst PR prolongations by flecainide were larger in humans for equal prolongations in dogs. Different administration routes were used and may primarily have influenced the guinea pig to human translation of verapamil, as i.v. infusion of verapamil induces more PR prolongation in humans than oral administration (Reiter et al., 1982) .Typical PR interval point baselines were 170 ms in humans, 103 ms in dogs (61% of human) and 62 ms in guinea pigs (37% of human), and absolute differences between effects in guinea pigs, dogs and humans were thus larger than relative differences. Similar results were acquired for translating effects of total and unbound drug in vivo as PPB fractions were similar between the species.
Translation method 2: middle-out translation to clinical PR prolongation. Practical identifiability issues led to a high correlation between E m and τ and was solved by fixing E m . Similar results were obtained, where simulations of optimized models with fixed E m values between 40 and 100 ms showed similar predictions up to 30 ms change
Figure 6
Top-down translation to PR prolongations in humans from (A) rCa v 1.2 binding at the diltiazem site in vitro, (B) PR prolongations in guinea pigs and (C) PR prolongations in dogs, by AZD1305, flecainide and verapamil. Effects of AZD1305 in guinea pigs were not available. The shaded areas represent the 95% CIs (darker areas) and PIs (lighter areas) overlaid for all compounds and species.
Figure 7
Middle-out translation of rCa v 1.2 binding at the diltiazem site to PR prolongation in the clinic. (A) Fit to data and typical parameter estimates for the system parameters for the operational model. (B) Model predicted and measured effects of flecainide and verapamil in humans. Predictions were generated using the estimated signal transduction parameters and the in vitro estimated binding in the rCa v 1.2 assay. Clinical data were collected from literature studies and represent effects in healthy volunteers (dark blue) and patients (light blue). (C) Model predicted translation between rCa v 1.2 binding in vitro and PR prolongation in humans, highlighting the 95% CI for % bound ion channel at 10% PR prolongation. (Figure in Supporting Information S3) . As the highest prolongations observed for all the compounds investigated were 56 ms, an E m value of 60 ms was selected. The operational model with E m = 60 ms well described AZD1305-induced PR prolongations ( Figure 7A ), although the high variability in the data led to wider CIs and PIs compared to the QRS model. The final estimate for the system parameter τ was lower for PR compared to QRS and with larger uncertainty (4.0 ± 0.7 vs. 8.0 ± 0.4), reflecting a less efficient signal transduction and reduced precision due to the more variable data. The exponent n was estimated to be 2.1 ± 0.2, suggesting some signal amplification. Baseline and effect compartment parameters were similar to the estimated values in the PKPD models (Supporting Information S2 and S3).
The systems parameters were combined with in vitro potency parameters for flecainide and verapamil and used to predict the PR prolongation of these compounds in the measured range of unbound concentrations ( Figure 7B ). To account for the different potency and metabolism of the two verapamil enantiomers (Echizen et al., 1985a,b) , the efficacy of verapamil was assumed to be mediated only by the more potent S enantiomer. The estimated K i for verapamil of 0.044 μM was therefore corrected to account to the predicted enantiomer composition in vivo by K i,invivo = K i * 0.5/0.18 (fraction S enantiomer in vitro/fraction S enantiomer in vivo; human verapamil ratio: Echizen et al., 1985b) . PR prolongations induced by flecainide were slightly over-predicted, while verapamil effects were well predicted by the model.
The translational relationship between bound rCa v 1.2 and PR prolongation in humans was simulated, and the CIs and PIs were generated ( Figure 7C ). These results predict that 15% (CI range: 12-22%) binding of rCa v 1.2 at the diltiazem site is required to induce 10% PR prolongation.
Discussion and conclusions
Small in vitro interactions lead to relevant QRS/PR prolongations
Translation between in vitro effects and QRS/PR change in humans show that relatively low hNa v 1.5 inhibition (3-7%) and rCa v 1.2 binding (13-21%) correlate with 10% QRS/PR change ( Figures 3A and 6A) . Translation using the middleout approach resulted in similar thresholds, strengthening the confidence in the predicted relationships. Since only low inhibition/binding is necessary to induce human QRS/PR changes, using IC 50 in margin calculations may overstate or understate risk when Hill (sigmoidicity) factors are different from 1, as Hill factors have a high impact at these inhibition levels. For example, 10% inhibition occurs at concentrations nine times lower than IC 50 with a Hill factor of 1, but only four times lower with a Hill factor of 1.5. Concentrations corresponding to inhibitions leading to a meaningful human change may therefore provide safer margins, such as 5% hNa v 1.5 inhibition and 15% rCa v 1.2 binding. However, technical issues may lead to difficulties measuring these relatively small inhibition levels and to large variability in the range of IC 5 -IC 15 compared with IC 50 . Therefore, it is important that the full concentration-response curve is considered, and extrapolation from IC 50 values as has been done for unbound C max and hERG channel inhibition (Redfern et al., 2003) .
In vitro to clinical translations to human QRS widenings were highly consistent, although QRS widening by flecainide was higher at similar inhibition levels compared to AZD1305 and quinidine ( Figure 3A) . This reflects the mechanisms of action of type 1a and 1c anti-arrhythmics (quinidine and flecainide, respectively), which bind to the open state of Na v 1.5 (Hondeghem, 1987) and dissociate to the closed states with different rates. Flecainide dissociates more slowly than quinidine (>1500 ms vs. 300-1500 ms; Wilde, 1998) , leading to increased accumulation of Na v 1.5 block between heart beats. More Na v 1.5 block, therefore, remains at the beginning of each action potential, causing more QRS widening.
Translation of in vitro effects to clinical PR prolongations was relatively consistent between the compounds investigated. Similar inhibition levels resulted in larger PR prolongations for verapamil, possibly resulting from differences in the selectivity of the compounds towards additional binding sites on Ca v 1.2, as verapamil binds to the verapamil site on Ca v 1.2 in addition to the diltiazem site (Table 1) . Also, while QRS prolongations are strongly linked to the block of a single ion channel, multiple mechanisms contribute to AZD1305-, flecainide-and verapamil-induced PR prolongations that were not taken into account in this work. For example, AZD1305 and flecainide prolong the P wave (by Na v 1.5 block), and flecainide also reduces intracellular Ca 2+ release (Watanabe et al., 2009; Bannister et al., 2015) . While the top-down in vitro to clinical relationships provide predictions of human effects at specific in vitro levels such as the predicted therapeutic C max , they cannot directly be used to predict effects at full PK curves. However, this is possible with the semi-mechanistic approach using the estimated system parameters in combination with in vitro (unbound) potency. Such predictions may be used to predict exposure-effect relationships as exemplified in Figures 4B and 7B , or alternatively over time simulating QRS/PR effects at a predicted PK. While large QRS/PR effects may be under-predicted due to the assumed maximal (E m ) values, such large side effects are unlikely to occur. This approach may also be used to combine all available data (or data only for reference compounds) to estimate systems parameters to predict clinical effects of unknown entities. The approach has yet to be proven by predicting clinical PR and QRS change using preclinical data of an unknown entity.
QRS and PR prolongations are smaller in dogs and guinea pigs compared to humans
The translational relationships for QRS/PR effects demonstrated smaller changes at matched exposures in the nonclinical species than in humans. However, across compounds, the effects were consistent, especially for QRS where low % changes were three to four times larger in humans than in dogs. PR translations were more variable, with human changes one to four times larger than with dogs. Fewer compounds were investigated in guinea pigs, reducing the confidence in these results and limiting the possibility to evaluate the consistency in the translation between compounds. However, guinea pigs did show similar trends as dogs, with lower sensitivity than humans.
It is important to note that the levels of effects in dogs and guinea pigs that correspond to meaningful clinical changes of 10% (2-5% for QRS, 2-10% for PR) are well below the effect levels that these studies are typically powered for (guinea pig: 19/21% QRS/PR; Marks et al., 2012) . However, this power analysis is based on point-wise statistics, whereas employing a PKPD modelling approach increases sensitivity and specificity (Gotta et al., 2015) as all dose levels and time points are used simultaneously. Conducting PKPD modelling of nonclinical in vivo data as a routine analysis is therefore recommended to improve power to identify small QRS/PR effects. Furthermore, nonclinical effects should be evaluated well above the expected therapeutic exposure to ensure that potential side effects in cardiac conduction are developed.
Possible mechanisms for the reduced sensitivity of dogs and guinea pigs
Anatomically, guinea pig and dog hearts are 300 and 6 times lighter than human hearts (Joseph, 1908) and have smaller specialized tissues, for example, AV node (reviewed in Abolghassem, 2009 ) resulting in shorter QRS and PR intervals. Therefore, evaluating relative rather than absolute changes from baseline reduces the translational gap between guinea pigs, dogs and humans.
A major assumption is that the in vitro, in vivo and clinical (unbound) plasma concentrations are all equivalent to the target tissue exposure. For these compounds, the same unbound fraction was applied as the PPBs measured were similar across species, and considered to be within the variability of the assay. However, small errors in these fractions have a direct impact on the translational relationships, and highquality data of the free fractions in each species could potentially improve precision in the translational relationships. Errors in PPB are, however, unlikely to cause the high differences in sensitivity. Exposures at the target sites may also differ between species due to differences in the distribution to the heart tissue and intra-cellular targets.
The reduced sensitivity of guinea pigs and dogs to conduction slowing is likely to be present at the tissue level as flecainide and quinidine reduce the depolarization rate more in human atrial tissue than in guinea pig, rabbit and dog (Wang et al., 1990) . It is not known if in vitro studies using guinea pig and dog Na v /Ca v would indicate reduced potency compared with human Na v /Ca v . Ca v 1.2 is multifunctional with many splice variants (Hofmann et al., 2014) which could potentially differ between species; 94-98% amino acid homology of Na v 1.5 between mice, rats, pigs and humans (Zimmer et al., 2002; Blechschmidt et al., 2008) indicate that Na v 1.5 is highly conserved between species. However, the relative quantity of different isoforms of Na v varies throughout the conduction system (reviewed in Haufe et al., 2007) and between species (Blechschmidt et al., 2008) . Also, the density of other ion channels may contribute to the differences in sensitivity. This has been suggested for QT prolongation, where higher densities of K ir 2.1 and Kmin in dogs increase the repolarization reserve, reducing repolarization slowing due to ERG block (Jost et al., 2013) . Thus, conduction slowing may differ between species partly due to differences in the relative quantity of ion channel isoforms and splice variants.
Limitations
One major limitation of this work is the low number of compounds that was used to investigate the translation to human effects for each endpoint (three for the in vitro and the in vivo dog and one to two for the in vivo guinea pig). Historical studies were used for this analysis, and the number of compounds was therefore limited by the availability of sufficient data from the models investigated. The low number of compounds is a consequence of the fact that compounds with potency against these targets are typically screened out prior to in vivo and clinical studies. Also, the data sets were incomplete as data for two of the test compounds were not available in guinea pig. Although these limitations may be partly overcome by strengthening each individual translation by applying all in vitro and in vivo relationships suggested in this work, additional investigations into these translational relationships are important to increase confidence in human predictions. All in vivo studies were conducted with small group sizes of at the most four animals per treatment group. However, applying PKPD modelling to analyse these data allows simultaneous analysis of data across treatments and time points, thus increasing both sensitivity and specificity of the analysis (Gotta et al., 2015) .
Applying the translational relationships to reduce conduction liabilities
Prior to this study, no quantitative information was available on the relative sensitivity to drug-induced QRS/PR effects in nonclinical species and humans. Although this study is limited by the low number of investigated compounds, it provides a starting point for nonclinical assessment of conduction liabilities and predictions to humans. Improved sensitivity to detect potential liabilities of compounds in drug discovery can reduce animal use, as potentially unsafe drugs can be discontinued at an earlier stage, with clear relevance for the replacement, refinement or reduction (the 3Rs). Compounds with different mechanisms of action were investigated to account for possible compound-specific differences and to achieve a broader applicability of the recommendations and translational relationships of this work. Despite the relatively consistent in vitro to clinical translations for the investigated compounds, the influence of drug-ion channel kinetics and other mechanisms on QRS/PR prolongations highlight the importance of also evaluating drug effects in vivo.
This study has not defined a threshold for clinical QRS/PR effects that should be avoided, but has considered a 10% change in humans to be meaningful and then observed what the nonclinical in vitro or in vivo change was at matched concentrations. Resulting nonclinical changes at 10% or any preferred level of change in humans (Figures 3 and 6 ) may be used as first attempts to define margins for acceptable effects at expected unbound therapeutic concentrations, to be easily applied in early in vitro and in vivo safety assessment. Before FTIM studies, a more in-depth assessment of the therapeutic dose range may be required, such as clinical simulations of PR/QRS change over time using the predicted human PK. % BJP L Bergenholm et al.
QRS/PR change was up to four times larger in humans than in guinea pigs and dogs. This suggests that worst-case human QRS/PR effects may be predicted by simulating four times larger slopes than dogs and guinea pigs, while also accounting for baseline and protein binding differences. To include a measure of uncertainty, a best-case scenario may also be predicted by a two times larger (QRS) or the same (PR) slope. Although small distributional delays may be present, QRS and PR effects are likely to be well approximated by a direct effect model. In addition, the in vitro system models can complete the risk assessment by predicting QRS/PR effects at the predicted PK. Considering the small compound set (one to three compounds per nonclinical assay and endpoint), additional analyses should be conducted to strengthen the suggested nonclinical margins and translational relationships. Several independent predictions of clinical effects provide additional confidence, and any discordance offers a measure of the uncertainty regarding the human prediction. Therefore, a combined view applying information from in vitro and in vivo studies is vital to predict cardiac conduction risks before FTIM studies, using the preliminary translational relationships suggested in this work to build on an integrated package of evidence of clinical QRS/PR risk.
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Supporting Information S1 Literature study and modelling of clinical QRS/PR effects of flecainide, quinidine and verapamil. Figure S1 QRS (left column, green colour) and PR (right column, blue colour) prolongations in healthy volunteers (circles) and patients (squares) induced by A/B. flecainide, C. quinidine and D. verapamil. Data points represent associated plasma concentration-ECG pairs (1-8 per published study) with standard errors where available. Brown colours represent data excluded prior to modelling. Table S1 Identified published studies of QRS widening and PR prolongation following A. flecainide, B. quinidine and C. verapamil treatment in humans. Table S2 Parameter values and standard errors for the final regression models. Drug effect parameters describe the effect of unbound drug in plasma. Figure S2 QRS (left column, green markers) and PR (right column, blue markers) prolongations in healthy volunteers (circles) and patients (squares) induced by A/B. flecainide, C. quinidine and D. verapamil. Data points represent associated plasma concentration-ECG pairs (1-8 per published study) with standard errors where available. The shaded areas represent the 95% confidence intervals (darker area) and prediction intervals (lighter area). Brown colours represent data excluded during regression analysis (A) and repeated dosing data (D). Figure S3 Goodness of fit plots for the final regression models for flecainide-induced QRS prolongations (first row) and PR prolongations (second row). Figure S4 Goodness of fit plots for the final regression model for quinidine-induced QRS prolongations. Figure S5 Goodness of fit plots for the final regression model for verapamil-induced PR prolongations following acute (black squares/solid line) and chronic (red circles/dashed line) dosing. Supporting Information S2 PKPD modelling of guinea pig and human data. Figure S6 A. Observed data and individual predictions for flecainide plasma concentrations following iv infusion in guinea pig. Different colour for each subject. B. Estimated PK model parameters describing flecainide plasma concentrations following iv dosing in guinea pig. Figure S7 A. Observed data and individual predictions with different colour for each subject. B. Estimated parameters for PR intervals following vehicle and flecainide intravenous infusions in guinea pig.
a BSV (between-subject variability) are presented as coefficient of variation, calculated by the approximation CV% = ω*100 for log-normal distributions. Figure S8 A. Observed data and individual predictions with different colour for each subject. B. Estimated parameters for PR intervals following vehicle and flecainide intravenous infusions in guinea pig. a BSV (between-subject variability) are presented as coefficient of variation, calculated by the approximation CV% = ω*100 for log-normal distributions. Figure S9 A. Observed data and individual predictions for verapamil plasma concentrations following iv infusion in guinea pig. Different colour for each subject. B. Estimated PK model parameters describing verapamil plasma concentrations following iv dosing in guinea pig. Figure S10 A. Observed data and individual predictions with different colour for each subject and B. estimated parameters for PR intervals following vehicle and verapamil intravenous infusions in guinea pig. a BSV (between-subject variability) are presented as coefficient of variation, calculated by the approximation CV% = ω*100 for log-normal distributions. Table S3 Estimated PK model parameters describing plasma AZD1305 concentrations following iv and oral dosing. Figure S11 AZD1305 plasma concentration and QRS interval duration data (markers) and model predictions (lines) for humans treated with AZD1305. Individual subjects are separated by colour. Figure S12 AZD1305 plasma concentration and PR interval duration data (markers) and model predictions (lines) for humans treated with AZD1305. Individual subjects are separated by colour. Figure S13 Predicted AZD1305-QRS prolongation relationship (left) and hNav1.5 inhibition-QRS widening relationship for operational models with E m fixed at 40, 60, 80 and 100 ms (followed by estimation of the remaining parameters) show that QRS widenings up to 20 ms are predicted similarly despite the fact that E m is varied. Figure S14 Predicted AZD1305-PR prolongation relationship (left) and rCav1.2 binding-QRS widening relationship for operational models with E m fixed at 40, 60, 80 and 100 ms (followed by estimation of the remaining parameters) show that PR prolongations up to 30 ms are predicted similarly despite the fact that E m is varied.
